Breast Cancer Therapeutics Market Size, Share, Trends, Growth 2032

Breast Cancer Therapeutics Industry Prospective:

The global breast cancer therapeutics market size was evaluated at $30 billion in 2023 and is slated to hit $58 billion by the end of 2032, with a CAGR of nearly 8% between 2024 and 2032. 

Request Free Sample  

Breast Cancer Therapeutics Market: Overview

Breast cancer therapeutics includes various therapies such as radiation therapy, chemotherapy, surgery, hormone therapy, immunotherapy, and targeted therapy. Current breakthroughs in this domain include new drug development and treatment regimes for enhancing patient outcomes. Furthermore, there are various treatments for breast cancer that include RNA-based breast cancer therapies, bi-specific antibodies, and CAR-T cell therapies.

Key Insights

• As per the analysis shared by our research analyst, the global breast cancer therapeutics market is projected to expand annually at the annual growth rate of around 8% over the forecast timespan (2024-2032)
• In terms of revenue, the global breast cancer therapeutics market size was evaluated at nearly $30 billion in 2023 and is expected to reach $58 billion by 2032.
• The global breast cancer therapeutics market is anticipated to grow rapidly over the forecast timeline owing to rising cases of breast cancer along with breakthroughs in therapeutics.
• In terms of therapy type, the targeted therapy segment is slated to register the highest CAGR over the forecast period.
• Based on drug class, the monoclonal antibodies segment is predicted to contribute majorly towards segmental space in the upcoming years.
• On the basis of distribution channel, the hospital pharmacies segment is projected to dominate the global market revenue over 2024-2032
• Region-wise, the Asia-Pacific breast cancer therapeutics industry is projected to register the fastest CAGR during the assessment timespan.

Breast Cancer Therapeutics Market: Growth Factors

An increase in the incidences of breast cancer to boost the global market surge over 2024-2032

Rising cases of breast cancer, along with breakthroughs in therapeutics, are expected to spur the expansion of the global breast cancer therapeutics market. Furthermore, the rising elderly female population prone to breast cancer can multiply the global market surge in the years ahead.

Moreover, supportive government policies and massive healthcare spending in developed countries are anticipated to prop up the market surge globally in the years ahead. Need for quick detection of cancer, along with the launch of cancer screening systems, will spur the global market surge in the ensuing years.  

Breast Cancer Therapeutics Market: Restraints

Rising medical therapy charges can hinder the global industry expansion over the coming years

Surging medical treatment costs of breast cancer and side effects of breast cancer treatment can obstruct the global breast cancer therapeutics industry surge. Moreover, lack of access to advanced healthcare amenities can hamper the global industry expansion in the years ahead. Growing resistance to medicine and complex legislation can inhibit the industry surge in the ensuing years.

Breast Cancer Therapeutics Market: Opportunities

Launching precision medicine & introducing new treatment modes can create new growth facets for the global market

Introduction of personalized medicine and the launching of new methods of treating breast cancer are expected to generate new growth avenues for the global breast cancer therapeutics market. Moreover, the introduction of new antibody-drug conjugates will proliferate the global market size. Additionally, breakthroughs in diagnostics systems will propel the global market surge in the ensuing years.

Breast Cancer Therapeutics Market: Challenges

Low access to drugs for treating breast cancer can create hurdles in the growth path of the global industry

Less availability of medicines for treating breast cancer in emerging economies can challenge the global breast cancer therapeutics industry surge. Ethical issues arising while performing clinical trials on patients can severely impact the development of new modes of treatment, thereby obstructing the global industry expansion.   

Breast Cancer Therapeutics Market: Segmentation

The global breast cancer therapeutics market is divided into therapy type, drug class, distribution channel, and region.             

In terms of therapy type, the breast cancer therapeutics market across the globe is segmented into hormone therapy, chemotherapy, targeted therapy, and immunotherapy segments. Apparently, the targeted therapy segment, which gathered nearly 55% of the global market earnings in 2023, is expected to record the fastest CAGR in the coming eight years.

This can be due to the fewer side effects caused by targeted therapy and the ability of targeted therapies to be customized to the patient’s genetic profile. Reportedly, pharmaceutical firms are creating novel targeted treatment regimens for treating patients.

Based on drug class, the global breast cancer therapeutics industry is divided into monoclonal antibodies, hormonal agents, and small molecule inhibitors segments. Apparently, the monoclonal antibodies segment, which dominated the global industry size in 2023, is anticipated to account largely towards the segment's progress in the forecasting timeline, which can be owing to their fewer side effects and versatile nature.

On the basis of distribution channel, the global breast cancer therapeutics market is bifurcated into online pharmacies, hospital pharmacies, and retail pharmacies segments. Moreover, the hospital pharmacies segment, which accounted for the major share of the global market in 2023, is likely to lead the global market earnings in the forecast period.

The growth of the segment over 2024-2032 can be credited to the easy availability of medicines in hospital pharmacies. Moreover, hospital pharmacies can offer easy accessibility to medicines and effectively handle drug side effects. Reportedly, pharmacists at hospital pharmacies offer medical support to subjects undergoing breast cancer treatment,

Breast Cancer Therapeutics Market: Report Scope

Breast Cancer Therapeutics Market: Regional Insights

North America is likely to maintain leading status in the global market over the assessment timeline

North America, which accounted for nearly 51% of the global breast cancer therapeutics market revenue in 2023, is predicted to establish a number one position in the global market in the forecasting timeline.

Furthermore, the regional market upsurges in the coming few years can be attributed to the presence of key pharmaceutical firms in countries such as the U.S. Presence of robust healthcare infrastructure in the region and easy acceptance of new modes of treating cancer has boosted the market evolution in North America. Strong law enforcement with a view to ensuring drug safety has impelled the regional market trends.

Asia-Pacific breast cancer therapeutics industry is set to account for the highest compound rate of growth annually in the forecast timespan. The scaling up of the industry in APAC can be subject to a surge in the cases of breast cancer patients in both rural and urban areas of emerging economies in Asia.

In addition, supportive government schemes allocating huge funds for the healthcare sector will generate a profitable growth map for the industry in APAC.  

Breast Cancer Therapeutics Market: Competitive Space

The global breast cancer therapeutics market profiles key players such:

• Halozyme Therapeutics
• Macrogenics Inc.
• Celgene Corporation
• Roche Holding AG
• Novartis AG
• AstraZeneca PLC
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Sanofi S.A.
• Pfizer Inc.
• Roche Holding AG
• Johnson & Johnson
• AbbVie Inc.
• Onyx Pharmaceuticals
• Merck & Co. Inc.

The global breast cancer therapeutics market is segmented as follows:

By Therapy Type

• Hormone Therapy
• Chemotherapy
• Targeted Therapy
•  Immunotherapy

By Drug Class

• Monoclonal Anti-bodies
•  Hormonal Agents
• Small Molecule Inhibitors

By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
•  Retail Pharmacies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa